Skip to Main Content

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

The readout of Alnylam Pharmaceuticals’ APOLLO-B Phase 3 study is one of the biggest clinical trial catalysts of the year. The study is attempting to expand the use of Alnylam’s approved RNA-interference medicine Onpattro to encompass a significantly larger group of patients with transthyretin amyloidosis cardiomyopathy, or ATTR-CM, a progressive heart disease caused by the buildup of a toxic protein. APOLLO-B is also high risk, given the uncertainties raised last year when a similar study conducted by BridgeBio delivered negative results.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment